Despite recent improvements in healthcare outcomes in Hungary, the country remains far frombridging the gap with its Western European counterparts. The most prominent reason behind this is the lackof funding within the healthcare system - a factor that is holding back emerging European healthcaresystems as a whole. Ultimately, this will limit drugmaker opportunities in Hungary due to poor access toinnovative medicines.
Headline Expenditure Projections
Pharmaceuticals: HUF731bn (USD2.60bn) in 2016 to HUF763bn (USD2.71bn) in 2017; +4.3% in localcurrency terms and 4.3% in US dollar terms. Forecast increased from last quarter.
Healthcare: HUF2.63trn (USD9.33bn) in 2016 to HUF2.80trn (USD9.94bn) in 2017; +6.6% in localcurrency terms and 6.5% in US dollar terms. Forecast in US dollar terms revised upwards from lastquarter.
A report by the State Health Care Centre (ÁEEK) in June 2017 highlighted that 26% of deaths in 2014(approximately 32,000) could have been prevented. The report stated these deathslikely happened due toinefficient use of healthcare funds and underfunding of Hungary's healthcare system.